Biased Ligands. Better Drugs.

TRV734 Phase 1 clinical studies

TRV734, a G Protein-biased Ligand of the ยต-opioid Receptor, Demonstrates Oral Bioavailability, Displays Predictable Pharmacokinetics and Pharmacodynamics, and Provides Analgesia in Healthy Adults

Franck Skobieranda, MD, Ian E. James, PhD, Michael J. Fossler, PharmD, PhD, David G. Soergel, MD.

View PDF

Copyright © Trevena, Inc.